Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …

Abstract PD-1/PD-L1 immune checkpoint blockade therapy has become an effective method
for the treatment of cancers in the clinic. It has great clinical advantages and therapeutic …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

A particularly promising cancer treatment is the use of monoclonal antibodies (mAbs)
against immune checkpoints (ie, immune checkpoint inhibitors; ICIs). However, many …

Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory
mechanisms that modulate immunosuppression in patients with cancer. In exposure to …

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing
oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions …

Several cancers are highly refractory to conventional chemotherapy. The survival of tumors
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …

The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …

The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …